1. Home
  2. PROK vs FRBA Comparison

PROK vs FRBA Comparison

Compare PROK & FRBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • FRBA
  • Stock Information
  • Founded
  • PROK 2015
  • FRBA 2007
  • Country
  • PROK United States
  • FRBA United States
  • Employees
  • PROK N/A
  • FRBA N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • FRBA Major Banks
  • Sector
  • PROK Health Care
  • FRBA Finance
  • Exchange
  • PROK Nasdaq
  • FRBA Nasdaq
  • Market Cap
  • PROK 271.2M
  • FRBA 316.4M
  • IPO Year
  • PROK N/A
  • FRBA N/A
  • Fundamental
  • Price
  • PROK $2.33
  • FRBA $14.94
  • Analyst Decision
  • PROK Buy
  • FRBA Buy
  • Analyst Count
  • PROK 3
  • FRBA 1
  • Target Price
  • PROK $4.00
  • FRBA $18.00
  • AVG Volume (30 Days)
  • PROK 372.7K
  • FRBA 36.0K
  • Earning Date
  • PROK 08-09-2024
  • FRBA 10-23-2024
  • Dividend Yield
  • PROK N/A
  • FRBA 1.63%
  • EPS Growth
  • PROK N/A
  • FRBA N/A
  • EPS
  • PROK N/A
  • FRBA 1.23
  • Revenue
  • PROK N/A
  • FRBA $114,389,000.00
  • Revenue This Year
  • PROK N/A
  • FRBA N/A
  • Revenue Next Year
  • PROK N/A
  • FRBA $9.29
  • P/E Ratio
  • PROK N/A
  • FRBA $12.03
  • Revenue Growth
  • PROK N/A
  • FRBA 20.16
  • 52 Week Low
  • PROK $1.12
  • FRBA $10.51
  • 52 Week High
  • PROK $8.56
  • FRBA $15.70
  • Technical
  • Relative Strength Index (RSI)
  • PROK 51.06
  • FRBA 53.23
  • Support Level
  • PROK $2.07
  • FRBA $15.11
  • Resistance Level
  • PROK $2.45
  • FRBA $15.66
  • Average True Range (ATR)
  • PROK 0.17
  • FRBA 0.35
  • MACD
  • PROK 0.01
  • FRBA -0.06
  • Stochastic Oscillator
  • PROK 68.42
  • FRBA 40.98

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

About FRBA First Bank

First Bank is a full-service commercial bank, with an emphasis on providing personal and business financial services to individuals and small to mid-sized businesses. The Bank provides its customers with a variety of financial services targeting all segments of the retail and corporate market. Its Business Banking offers commercial deposit accounts, business loans, online banking, and cash management.

Share on Social Networks: